North America Companion Diagnostics Market (2019-2025)
The North America Companion Diagnostics Market would witness market growth of 19.8% CAGR during the forecast period (2019-2025).
Companion Diagnostics is used to determine who would benefit from the treatment and it is useful to identify not only if someone is unable to be cured, but can also detect if a patient shows a tendency of being harmed by the use of specific drugs used to treat them. Technological advances have introduced many modifications to the treatment approach against diseases. Companion diagnostics is associated with a growing need for improved personalized patient treatment that provides health care professionals and their patients a favorable outcome of treatment assurance, as opposed to traditional treatment methods. Companion diagnostics will also have a major effect on the area of oncology therapy.
Targeted therapies have been developed in oncology and other fields and therefore demand for companion diagnostics has risen. Moreover, market growth among end-user industries like pharmaceutical and biotechnology firms is growing, who are willing to introduce new drugs on the market more quickly with lower-cost clinical trials as they have lowered their time and cost.
Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
Scope of the Study
Market Segmentation:
By Technology
Companion Diagnostics is used to determine who would benefit from the treatment and it is useful to identify not only if someone is unable to be cured, but can also detect if a patient shows a tendency of being harmed by the use of specific drugs used to treat them. Technological advances have introduced many modifications to the treatment approach against diseases. Companion diagnostics is associated with a growing need for improved personalized patient treatment that provides health care professionals and their patients a favorable outcome of treatment assurance, as opposed to traditional treatment methods. Companion diagnostics will also have a major effect on the area of oncology therapy.
Targeted therapies have been developed in oncology and other fields and therefore demand for companion diagnostics has risen. Moreover, market growth among end-user industries like pharmaceutical and biotechnology firms is growing, who are willing to introduce new drugs on the market more quickly with lower-cost clinical trials as they have lowered their time and cost.
Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
Scope of the Study
Market Segmentation:
By Technology
- Immunohistochemistry
- Polymerase chain reaction (PCR)
- Next generation sequencing (NGS)
- In Situ Hybridization and
- Other Technology
- Oncology
- Neurology and
- Other Indications
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Blood Cancer and
- Other Cancer Type
- US
- Canada
- Mexico
- Rest of North America
- Agilent Technologies, Inc.
- Almac Group
- ARUP Laboratories, Inc.
- Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
- Danaher Corporation
- Thermo Fisher Scientific, Inc.
- Hologic, Inc.
- Novartis AG
- Illumina, Inc.
- Qiagen N.V.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Companion Diagnostics Market, by Technology
1.4.2 North America Companion Diagnostics Market, by Indication
1.4.3 North America Companion Diagnostics Market, by Cancer Type
1.4.4 North America Companion Diagnostics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Executive Summary
2.1.3 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY
3.1 North America Immunohistochemistry Market by Country
3.1.1 North America Polymerase chain reaction (PCR) Market by Country
3.1.2 North America Next generation sequencing (NGS) Market by Country
3.1.3 North America In Situ Hybridization Market by Country
3.1.4 North America Other Technology Market by Country
CHAPTER 4. NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION
4.1 North America Oncology Companion Diagnostics Market by Country
4.2 North America Neurology Companion Diagnostics Market by Country
4.3 North America Other Indications Companion Diagnostics Market by Country
CHAPTER 5. NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE
5.1 North America Breast Cancer Companion Diagnostics by Country
5.2 North America Colorectal Cancer Companion Diagnostics by Country
5.3 North America Lung Cancer Companion Diagnostics by Country
5.4 North America Blood Cancer Companion Diagnostics by Country
5.5 North America Other Cancer Type Companion Diagnostics Market by Country
CHAPTER 6. NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY
6.1 USA Companion Diagnostics Market
6.1.1 USA Companion Diagnostics Market by Technology
6.1.2 USA Companion Diagnostics Market by Indication
6.1.2.1 USA Companion Diagnostics Market by Cancer Type
6.2 Canada Companion Diagnostics Market
6.2.1 Canada Companion Diagnostics Market by Technology
6.2.2 Canada Companion Diagnostics Market by Indication
6.2.2.1 Canada Companion Diagnostics Market by Cancer Type
6.3 Mexico Companion Diagnostics Market
6.3.1 Mexico Companion Diagnostics Market by Technology
6.3.2 Mexico Companion Diagnostics Market by Indication
6.3.2.1 Mexico Companion Diagnostics Market by Cancer Type
6.4 Rest of North America Companion Diagnostics Market
6.4.1 Rest of North America Companion Diagnostics Market by Technology
6.4.2 Rest of North America Companion Diagnostics Market by Indication
6.4.2.1 Rest of North America Companion Diagnostics Market by Cancer Type
CHAPTER 7. COMPANY PROFILES
7.1 Agilent Technologies, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Product launches:
7.1.5.2 Expansions:
7.2 Almac Group
7.2.1 Company Overview
7.2.1 Recent strategies and developments:
7.2.1.1 Collaborations, partnerships and agreements:
7.3 ARUP Laboratories, Inc.
7.3.1 Company Overview
7.4 Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.5 Danaher Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Acquisition and mergers:
7.6 Thermo Fischer Scientific, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Expansions:
7.7 Hologic, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product launches:
7.7.5.2 Acquisition and mergers:
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.9 Illumina, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Product launches:
7.9.5.2 Acquisition and mergers:
7.9.5.3 Collaborations, partnerships and agreements:
7.1 Qiagen N.V.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Product launches:
7.10.5.2 Collaborations, partnerships and agreements:
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Companion Diagnostics Market, by Technology
1.4.2 North America Companion Diagnostics Market, by Indication
1.4.3 North America Companion Diagnostics Market, by Cancer Type
1.4.4 North America Companion Diagnostics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Executive Summary
2.1.3 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY
3.1 North America Immunohistochemistry Market by Country
3.1.1 North America Polymerase chain reaction (PCR) Market by Country
3.1.2 North America Next generation sequencing (NGS) Market by Country
3.1.3 North America In Situ Hybridization Market by Country
3.1.4 North America Other Technology Market by Country
CHAPTER 4. NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION
4.1 North America Oncology Companion Diagnostics Market by Country
4.2 North America Neurology Companion Diagnostics Market by Country
4.3 North America Other Indications Companion Diagnostics Market by Country
CHAPTER 5. NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE
5.1 North America Breast Cancer Companion Diagnostics by Country
5.2 North America Colorectal Cancer Companion Diagnostics by Country
5.3 North America Lung Cancer Companion Diagnostics by Country
5.4 North America Blood Cancer Companion Diagnostics by Country
5.5 North America Other Cancer Type Companion Diagnostics Market by Country
CHAPTER 6. NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY
6.1 USA Companion Diagnostics Market
6.1.1 USA Companion Diagnostics Market by Technology
6.1.2 USA Companion Diagnostics Market by Indication
6.1.2.1 USA Companion Diagnostics Market by Cancer Type
6.2 Canada Companion Diagnostics Market
6.2.1 Canada Companion Diagnostics Market by Technology
6.2.2 Canada Companion Diagnostics Market by Indication
6.2.2.1 Canada Companion Diagnostics Market by Cancer Type
6.3 Mexico Companion Diagnostics Market
6.3.1 Mexico Companion Diagnostics Market by Technology
6.3.2 Mexico Companion Diagnostics Market by Indication
6.3.2.1 Mexico Companion Diagnostics Market by Cancer Type
6.4 Rest of North America Companion Diagnostics Market
6.4.1 Rest of North America Companion Diagnostics Market by Technology
6.4.2 Rest of North America Companion Diagnostics Market by Indication
6.4.2.1 Rest of North America Companion Diagnostics Market by Cancer Type
CHAPTER 7. COMPANY PROFILES
7.1 Agilent Technologies, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Product launches:
7.1.5.2 Expansions:
7.2 Almac Group
7.2.1 Company Overview
7.2.1 Recent strategies and developments:
7.2.1.1 Collaborations, partnerships and agreements:
7.3 ARUP Laboratories, Inc.
7.3.1 Company Overview
7.4 Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.5 Danaher Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Acquisition and mergers:
7.6 Thermo Fischer Scientific, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Expansions:
7.7 Hologic, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product launches:
7.7.5.2 Acquisition and mergers:
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.9 Illumina, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Product launches:
7.9.5.2 Acquisition and mergers:
7.9.5.3 Collaborations, partnerships and agreements:
7.1 Qiagen N.V.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Product launches:
7.10.5.2 Collaborations, partnerships and agreements:
LIST OF TABLES
TABLE 1 NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 4 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 5 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 NORTH AMERICA IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 NORTH AMERICA IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 NORTH AMERICA OTHER TECHNOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 NORTH AMERICA OTHER TECHNOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 16 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 17 NORTH AMERICA ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 NORTH AMERICA ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 NORTH AMERICA NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 NORTH AMERICA NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 NORTH AMERICA OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 NORTH AMERICA OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 24 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 25 NORTH AMERICA BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 NORTH AMERICA BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 NORTH AMERICA COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 28 NORTH AMERICA COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 29 NORTH AMERICA LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 NORTH AMERICA LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 NORTH AMERICA BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 NORTH AMERICA BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 NORTH AMERICA OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 34 NORTH AMERICA OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 35 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 USA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 38 USA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 39 USA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 40 USA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 41 USA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 42 USA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 43 USA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 44 USA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 45 CANADA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 46 CANADA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 47 CANADA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 48 CANADA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 49 CANADA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 50 CANADA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 51 CANADA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 52 CANADA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 53 MEXICO COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 54 MEXICO COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 55 MEXICO COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 56 MEXICO COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 57 MEXICO COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 58 MEXICO COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 59 MEXICO COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 60 MEXICO COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 61 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 62 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 63 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 64 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 65 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 66 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 67 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 68 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 69 KEY INFORMATION – AGILENT TECHNOLOGIES, INC.
TABLE 70 KEY INFORMATION – ALMAC GROUP
TABLE 71 KEY INFORMATION – ARUP LABORATORIES, INC.
TABLE 72 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 73 KEY INFORMATION – DANAHER CORPORATION
TABLE 74 KEY INFORMATION – THERMO FISHER SCIENTIFIC, INC.
TABLE 75 KEY INFORMATION – HOLOGIC, INC.
TABLE 76 KEY INFORMATION – NOVARTIS AG
TABLE 77 KEY INFORMATION – ILLUMINA, INC.
TABLE 78 KEY INFORMATION – QIAGEN N.V.
TABLE 1 NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 4 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 5 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 NORTH AMERICA IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 NORTH AMERICA IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 NORTH AMERICA OTHER TECHNOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 NORTH AMERICA OTHER TECHNOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 16 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 17 NORTH AMERICA ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 NORTH AMERICA ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 NORTH AMERICA NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 NORTH AMERICA NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 NORTH AMERICA OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 NORTH AMERICA OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 24 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 25 NORTH AMERICA BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 NORTH AMERICA BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 NORTH AMERICA COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 28 NORTH AMERICA COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 29 NORTH AMERICA LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 NORTH AMERICA LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 NORTH AMERICA BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 NORTH AMERICA BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 NORTH AMERICA OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 34 NORTH AMERICA OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 35 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 USA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 38 USA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 39 USA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 40 USA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 41 USA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 42 USA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 43 USA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 44 USA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 45 CANADA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 46 CANADA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 47 CANADA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 48 CANADA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 49 CANADA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 50 CANADA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 51 CANADA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 52 CANADA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 53 MEXICO COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 54 MEXICO COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 55 MEXICO COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 56 MEXICO COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 57 MEXICO COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 58 MEXICO COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 59 MEXICO COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 60 MEXICO COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 61 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 62 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 63 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 64 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 65 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 66 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 67 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 68 REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 69 KEY INFORMATION – AGILENT TECHNOLOGIES, INC.
TABLE 70 KEY INFORMATION – ALMAC GROUP
TABLE 71 KEY INFORMATION – ARUP LABORATORIES, INC.
TABLE 72 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 73 KEY INFORMATION – DANAHER CORPORATION
TABLE 74 KEY INFORMATION – THERMO FISHER SCIENTIFIC, INC.
TABLE 75 KEY INFORMATION – HOLOGIC, INC.
TABLE 76 KEY INFORMATION – NOVARTIS AG
TABLE 77 KEY INFORMATION – ILLUMINA, INC.
TABLE 78 KEY INFORMATION – QIAGEN N.V.
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
